生脉注射液联合利伐沙班用于急性冠脉综合征并心源性休克45例

Rivaroxaban Combined with Shengmai Injection for Treating Acute Coronary Syndrome Complicated Cardiogenic Shock in 45 Cases

目的探讨不同方式给予利伐沙班及生脉注射液用于急性冠脉综合征并发心源性休克的临床疗效。方法选择医院收治的患者90例,随机分为对照组和观察组,各45例。两组患者均给予抗休克和相应对症处理,对照组患者在经皮冠状动脉介入治疗(PCI)术后口服利伐沙班及使用微量泵持续静脉给予生脉注射液;观察组患者在PCI术前3 d口服利伐沙班并使用微量泵持续静脉给予生脉注射液,术后治疗同对照组,两组术后持续治疗10 d。结果治疗后,两组患者的血压均明显高于治疗前(P<0.05),心率均低于治疗前(P<0.05),且观察组在治疗24 h及治疗后血压及心率的改善幅度均显著优于对照组(P<0.05);两组患者心功能、凝血功能及血小板水平均得到显著改善(P<0.05),且观察组改善幅度更明显(P<0.05);两组患者不良反应均较较轻,组间比较,差异无统计学意义(P>0.05)。结论急性冠脉综合征并心源性休克患者PCI围手术期及术后给予利伐沙班和生脉注射液,能显著提高临床疗效,有效改善血压、心率及心功能、凝血功能和血小板水平,且无明显不良反应发生,值得临床推广。

Objective To investigate the clinical efficacy of different ways of giving rivaroxaban and Shengmai Injection in treating acute coronary syndrome complicated cardiogenic shock. Methods Totally 90 patients admitted to the hospital were randomly divided into the control group and the observation group,45 cases in each group. The two groups were given antishock and related symptomatic treat-ment,the control group was given rivaroxaban and micropump continuous intravenous Shengmai Injection after PCI;the observation group was given rivaroxaban and micro-pump continuous intravenous Shengmai Injection at 3 d before PCI,and the therapy after treat-ment as same as the control group. The two groups were treated for 10 d after operation. Results After treatment,the blood pressure of the two groups was significantly higher than before treatment（ P ﹤ 0. 05）,the heart rate was significantly lower than before treatment （ P ﹤ 0. 05）,in the treatment of 24 h and after treatment,the blood pressure and heart rate in the observation group were significantly improved compared with those in the control group（ P ﹤ 0. 05）;the cardiac function,blood coagulation and platelet in the two groups were significantly improved compared with before treatment（ P ﹤ 0. 05）,and the observation group improved more obviously（ P ﹤ 0. 05）. The occurrence rate of the adverse reactions had no significant difference between the two groups（ P ﹥ 0. 05）. Conclusion Rivaroxaban combined with Shengmai Injection in treating acute coronary syndrome complicated cardiogenic shock during perioperative and postoperation period can significantly improve the clinical effect,effectively improve blood pressure and heart rate,heart function,blood coagulation and platelet function without obvious adverse reactions,and is worth of clinical promotion.